Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-16 02:02 UTC

BIOMED PULSE

Wednesday, July 16, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Ebola Bundibugyo virus disease outbreak in DRC and Uganda has now surpassed 1,460 confirmed cases and 452 deaths as of July 1, making it the dominant global health emergency of 2026, with a WHO-declared PHEIC still active and the first therapeutic trial now enrolling patients. [1] [2]

Mood: High alert on multiple simultaneous outbreak fronts; cautious optimism as treatment science accelerates.

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS DISEASE - DRC AND UGANDA

  • As of July 1, 2026, the Bundibugyo virus disease (BVD) outbreak in DRC has reached 1,460 confirmed cases and 452 deaths, with sustained cross-border transmission to Uganda continuing. [1]
  • WHO declared this event a Public Health Emergency of International Concern (PHEIC) on May 22, 2026, after its first IHR Emergency Committee meeting; the designation stops short of pandemic emergency status. [3]
  • WHO issued its first comprehensive filovirus clinical management guidelines on June 17, covering all Ebola types and Marburg, directly in response to this outbreak. [4]
  • The PARTNERS clinical trial opened patient enrolment in DRC on July 2, 2026, marking the first formal therapeutic evaluation ever conducted for Bundibugyo virus disease. [2]
  • WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing on July 2, enabling rapid genetic confirmation of infection from blood samples. [5]
  • Africa CDC and WHO launched a joint continental Ebola preparedness and response plan on June 5, targeting USD 518 million to support African countries in containing the outbreak. [6]
  • CDC enhanced Ebola airport screening began at Washington-Dulles International Airport on May 21 and expanded to Atlanta on May 23, 2026, targeting travelers from affected regions. [7] [8]
  • WHO experts convened on May 28 assessed candidate vaccines and therapeutics for Bundibugyo virus, as no licensed products currently exist for this specific Ebola strain. [9]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP

  • The fifth WHO Disease Outbreak News report on the Andes hantavirus (ANDV) cluster, published July 2, 2026, confirmed additional cases since the outbreak was first notified on May 2, 2026, aboard the M/V Hondius cruise ship. [10]
  • The outbreak involved severe acute respiratory illness among passengers and crew, with cases spanning multiple countries and nationalities across the ship's manifest.
  • CDC provided ongoing hantavirus response updates through late June 2026, with risk to the general American public described as extremely low.

NIPAH VIRUS - INDIA AND BANGLADESH

  • On June 11, 2026, Kerala State, India confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district; the adult male patient presented with neurological symptoms after onset on May 30.
  • Earlier in 2026, two healthcare workers at a private hospital in Barasat, West Bengal were confirmed NiV-positive in January, and Bangladesh confirmed one NiV case in Rajshahi Division in February.

WEST NILE VIRUS AND VECTOR-BORNE DISEASE

  • CDC reported an early West Nile virus season with record case counts as of July 1, 2026, issuing a public advisory urging Americans to use mosquito bite prevention throughout the Independence Day holiday weekend.
  • CDC data from late April showed weekly ER visits for tick bites running higher than historical averages, signaling an intense 2026 tick season.

OTHER ACTIVE OUTBREAKS

  • CDC warns of an E. coli outbreak linked to recalled frozen blueberries as of July 7, 2026; consumers are advised not to eat the recalled product.
  • CDC's Salmonella outbreak linked to backyard poultry has sickened at least 150 additional people, with more than a quarter of cases in children under 5 years old as of May 2026.
  • A Listeria outbreak linked to requesón/soft ricotta cheese was flagged by CDC on June 5, 2026.
  • Infant botulism linked to Nara Organics Whole Milk Organic Infant Formula prompted a CDC alert on June 13, 2026, with parents urged to stop using the product immediately.
  • CDC activated its Emergency Operations Center on June 12, 2026, to respond to New World Screwworm cases, a parasitic fly infestation.
  • A new CDC Salmonella outbreak alert linked to frozen sprouted beans was posted on July 17, 2026, with 11 people across 10 states ill.
  • Yellow fever transmission persisted into 2026 across 6 countries from January through May 26, with a total of 79 human infections reported globally.
  • Measles affected 19,161 suspected cases across 58 of 64 districts in Bangladesh through early April 2026, per WHO notification.
  • A novel mpox recombinant virus combining genomic elements from both clade Ib and clade IIb strains was documented globally in February 2026, WHO confirmed; recombination occurred in co-infected individuals.
  • A human avian influenza A(H9N2) case was confirmed in Italy in March 2026 in a male traveler returning from Senegal, per WHO.

HEALTHCARE-ASSOCIATED INFECTIONS

  • New CDC data released July 15, 2026 show a decline in healthcare-associated infections (HAIs) in U.S. hospitals in 2023, highlighting improved patient safety practices.

🧬 LONGEVITY & AGING

NAD-PLUS HOMEOSTASIS AND BONE REPAIR IN AGING

  • A new study published in Bioactive Materials describes a senescent metabolism-modulating hierarchical scaffold that restores NAD-plus homeostasis and redox balance, specifically to improve bone repair in aged tissue.
  • The scaffold targets the well-established link between cellular senescence, declining NAD-plus levels, and impaired regenerative capacity in older bone.

DELIRIUM AS A BRIDGE FROM INFECTION TO DEMENTIA

  • Two Lancet Healthy Longevity commentaries published in mid-2026 examine evidence that delirium triggered by severe infection may be a mechanistic link between acute illness and subsequent dementia development in older adults.
  • The proposed pathway suggests that infection-induced neuroinflammation and delirium disrupt synaptic integrity in ways that accelerate long-term cognitive decline.

DEMENTIA PREVENTION: PREPARING FOR A NEW ERA

  • A Lancet Healthy Longevity perspective by Beeri and Gu calls for practical, population-level readiness for a dementia prevention era, emphasizing that interventions must account for real-world social and economic constraints rather than idealized clinical settings.

KAEMPFEROL FROM MORINGA AND LONGEVITY IN DROSOPHILA

  • Research published in Toxicology Reports found that kaempferol extracted from Moringa oleifera increased longevity and reduced efavirenz-induced functional senescence in Drosophila melanogaster fruit fly models.
  • Efavirenz is an antiretroviral drug; the study suggests that kaempferol's antioxidant and anti-senescent properties may counteract drug-induced accelerated aging signals.

HYPERTENSION, FRAILTY, AND AGING IN INDIA

  • A letter published July 7, 2026 in Blood Pressure links hypertension to frailty risk among middle-aged and older adults in India, drawing on the Longitudinal Ageing Study in India cohort data.

SOCIAL DETERMINANTS OF HEALTHY LONGEVITY

  • A comprehensive analysis published in a Russian public health journal identifies medical and social determinants of healthy longevity, including prevention strategy frameworks focused on lifestyle, health system access, and chronic disease control.

TAU, EMERIN, AND NEURODEGENERATION

  • A study in Nucleus (published July 7, 2026) found that the mechanically sensitive nuclear protein emerin is elevated in the context of tau-induced cytoskeletal remodeling in neurons, connecting nuclear mechanotransduction to tauopathy mechanisms relevant to Alzheimer's disease and other aging-related dementias.

CANCER PROJECTIONS AND AGING POPULATIONS

  • WHO projects global cancer cases will nearly double by 2050, reaching well above 20.6 million new cases annually from the current estimate, with aging populations identified as a primary demographic driver.
  • WHO currently records close to 10 million cancer deaths per year, or more than 26,000 deaths per day.

STEATOTIC LIVER DISEASE AND TOBACCO ACROSS DECADES

  • A study in Journal of Diabetes and Metabolic Disorders examined the global burden of metabolic dysfunction-associated steatotic liver disease attributable to tobacco from 1990 to 2023 and projects trends through 2038, finding tobacco remains a major modifiable driver of this age-related liver condition.

VISION AND HEARING IMPAIRMENT IN OLDER AUSTRALIANS

  • A nationally representative Lancet Global Health survey found significant rates of vision and hearing impairment among Australians aged 50 and older, with higher burden among Indigenous Australians, highlighting age-related sensory health disparities.

PHYSICAL ACTIVITY RESTRICTION AND CEREBROVASCULAR MORTALITY IN JAPAN

  • An ecological panel study across Japan's 47 prefectures (2013-2022) found that structural physical activity restrictions were associated with increased cerebrovascular and diabetes mortality and higher long-term care intensity, with a COVID-19 counterfactual analysis reinforcing the findings.

PAIN COMPLEXITY IN STROKE CARE FOR OLDER ADULTS

  • Two Lancet Healthy Longevity pieces published in June 2026 address pain as an underrecognized dimension of complexity in stroke care for older adults, calling for more integrated pain assessment in post-stroke recovery protocols.

💊 NEW CURES & APPROVALS

LEQEMBI IQLIK - EISAI INC (ALZHEIMER'S DISEASE)

  • Eisai Inc received a supplemental approval (SUPPL AP) for Leqembi IQLIK (lecanemab-irmb, BLA 761375), an anti-amyloid monoclonal antibody for Alzheimer's disease.
  • Lecanemab targets amyloid-beta aggregates in the brain, representing one of the few disease-modifying treatments for Alzheimer's with demonstrated slowing of clinical decline.

VERZENIO - ELI LILLY AND CO (CANCER)

  • Eli Lilly and Co received a supplemental approval for Verzenio (abemaciclib, NDA 208716), a CDK4/6 inhibitor used in hormone receptor-positive, HER2-negative breast cancer.

RINVOQ LQ - ABBVIE (IMMUNE-MEDIATED DISEASES)

  • AbbVie received a supplemental approval for Rinvoq LQ (upadacitinib, NDA 218347), a JAK1 selective inhibitor indicated for rheumatoid arthritis, atopic dermatitis, and other immune-mediated conditions.

RILPIVIRINE HYDROCHLORIDE - LAURUS (HIV)

  • Laurus received an original approval (ORIG AP) for a generic formulation of rilpivirine hydrochloride (ANDA 219788), a non-nucleoside reverse transcriptase inhibitor used in HIV-1 treatment.

GLEEVEC - NOVARTIS (CANCER)

  • Novartis received a supplemental approval for Gleevec (imatinib mesylate, NDA 021588), a BCR-ABL and c-KIT tyrosine kinase inhibitor used primarily in chronic myeloid leukemia and gastrointestinal stromal tumors.

NOTE: openFDA records for these approvals list no specific action dates; all appear as recent supplement or original approvals in the Drugs@FDA database.

🧪 CLINICAL TRIALS

PARTNERS TRIAL - BUNDIBUGYO VIRUS DISEASE THERAPEUTICS

  • WHO announced on July 2, 2026 that the PARTNERS clinical trial opened enrolment in DRC for patients with Ebola disease caused by Bundibugyo virus, the first-ever therapeutic trial for this specific pathogen. [2]
  • The trial represents a major international collaboration to identify effective treatments for a disease for which no licensed therapeutic currently exists. [2]

IL-15 SUPERAGONIST WITH OR WITHOUT VACCINE IN BIOCHEMICALLY RECURRENT PROSTATE CANCER

  • A trial registered at ClinicalTrials.gov (NCT07686380) is evaluating N-803 (an IL-15 superagonist) alone or combined with ETBX-071 vaccine in men with biochemically recurrent prostate cancer after stereotactic body radiation therapy.
  • Biochemically recurrent prostate cancer affects 30,000 to 50,000 U.S. men per year, defined by rising PSA after prior surgery or radiation; the trial targets 2026 enrollment.

JAK1/2 INHIBITOR RUXOLITINIB FOR IMMUNE BONE MARROW FAILURE

  • NCT05998408 is evaluating ruxolitinib, a JAK1/2 inhibitor, for relapsed or refractory immune bone marrow failure conditions including aplastic anemia and related blood cancers in a trial opened July 15, 2026.
  • The trial targets patients whose immune systems attack bone marrow cells, for whom current therapies have failed.

IV SARILUMAB PHASE 1B/2 IN RHEUMATOID ARTHRITIS

  • NCT07704580 is a Phase 1/2 study evaluating intravenous sarilumab (an IL-6 receptor antagonist) with or without conventional synthetic DMARDs in adults with rheumatoid arthritis, assessing pharmacokinetics and safety.

INOTUZUMAB OZOGAMICIN IN ACUTE LYMPHOBLASTIC LEUKEMIA

  • NCT01371630, a Phase I/II trial combining inotuzumab ozogamicin (an anti-CD22 monoclonal antibody linked to calicheamicin toxin) with combination chemotherapy in acute lymphoblastic leukemia, remains active with updated listing dated July 15, 2026.

N-ACETYL-D-MANNOSAMINE (ManNAc) IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS

  • NCT06664814, an open-label Phase 2 study of ManNAc in patients with primary focal segmental glomerulosclerosis (FSGS), a kidney scarring disease, is enrolling as of July 15, 2026 at NIH.
  • FSGS can progress to kidney failure requiring dialysis or transplant; ManNAc is being tested for its potential to reduce proteinuria and slow scarring.

📢 PUBLIC HEALTH

DRUG-RESISTANT BACTERIA ON THE RISE

  • A CDC report published September 23, 2025 found a dramatic increase in a dangerous type of drug-resistant bacteria in the United States, heightening concerns about antibiotic stewardship across healthcare settings.

CANCER GLOBAL BURDEN WARNING FROM WHO

  • WHO issued an urgent call to action on July 8, 2026, noting that global new cancer cases are projected to nearly double by 2050, with over 20.6 million new diagnoses currently per year and close to 10 million deaths annually.

UNSAFE FOOD MORTALITY STATISTICS FROM WHO

  • WHO released new global estimates on June 3, 2026 showing unsafe food causes 866 million illnesses and 1.5 million deaths annually, with children under 5 facing nearly three times the illness risk of older individuals.

EL SALVADOR ELIMINATES TRACHOMA

  • WHO validated El Salvador on July 13, 2026 as having eliminated trachoma as a public health problem; trachoma is the world's leading infectious cause of blindness.

U.S. WITHDRAWAL FROM WHO COMPLETED

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 failures, politicization, and a stated shift toward bilateral global health engagement.

CDC TRAVELER BIOSURVEILLANCE SURPASSES ONE MILLION PARTICIPANTS

  • CDC announced January 30, 2026 that its Traveler-Based Genomic Surveillance program has surpassed one million voluntary air travel participants, enhancing the agency's capacity to detect novel pathogens at ports of entry.

CDC IMMUNIZATION SCHEDULE UPDATES

  • CDC updated its immunization schedules in October 2025 to apply individual-based decision-making for COVID-19 vaccines and to allow standalone varicella (chickenpox) vaccination for toddlers.
  • In December 2025, CDC adopted individual-based decision-making for hepatitis B vaccination for infants born to hepatitis B virus-negative mothers, following ACIP vote.

PNEUMOCOCCAL VACCINE AGE LOWERED TO 50

  • CDC Director endorsed an ACIP recommendation lowering the recommended age for pneumococcal vaccination from 65 to 50 years old, effective October 23, 2024.

BIOMED PULSE is an informational summary only. Nothing here constitutes medical advice. Always consult a qualified healthcare provider for personal health decisions. Sources: CDC Newsroom, WHO Disease Outbreak News, WHO News, openFDA Drugs@FDA, ClinicalTrials.gov, Europe PMC/PubMed.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Patient enrolment begins in a scientific trial to identify the… — WHO News
  3. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  4. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  5. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  6. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. Experts convened by WHO advise on candidate treatments and vac… — WHO News
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260716-02-v29 · 2026-07-16 02:02 UTC · pulse.uzylab.com

Read next